Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis.

ABSTRACT:

Background and aim

Recent epidemiological studies indicated that metformin might improve the survival of various cancers. However, its benefit on pancreatic cancer was controversial.

Methods

We performed this meta-analysis to investigate the benefit of metformin on pancreatic cancer. A comprehensive literature search was performed through PubMed, Cochrane Library and Embase. Relative risk (RR) and hazard ratio (HR) with 95% confidence interval (CI) were pooled.

Results

The meta-analysis of 2 randomized controlled trials including181 pancreatic patients, revealed that metformin use was not associated with an improved overall survival at 6 months (RR=0.90, 95% CI=0.67-1.21), overall survival (HR=1.19, 95% CI=0.86-1.63) and progression-free survival (HR=1.39, 95% CI=0.97

SUBMITTER: Dong YW 

PROVIDER: S-EPMC5589674 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature